Media stories about Cancer Genetics (NASDAQ:CGIX) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cancer Genetics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 47.7773479709849 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Several equities analysts have recently issued reports on CGIX shares. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Cancer Genetics in a research note on Thursday, September 21st. Zacks Investment Research downgraded shares of Cancer Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Finally, ValuEngine downgraded shares of Cancer Genetics from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $5.42.

Shares of Cancer Genetics (CGIX) traded up $0.05 during midday trading on Friday, reaching $2.70. 19,607 shares of the company were exchanged, compared to its average volume of 102,744. Cancer Genetics has a fifty-two week low of $1.30 and a fifty-two week high of $5.30. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.18.

WARNING: “Cancer Genetics (CGIX) Getting Somewhat Favorable Media Coverage, Study Finds” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at

Cancer Genetics Company Profile

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Insider Buying and Selling by Quarter for Cancer Genetics (NASDAQ:CGIX)

Receive News & Ratings for Cancer Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.